Dabrafenib resistance

Dabrafenib is a BRAF inhibitor used to treat malignant tumors with BRAF V600E or V600K mutations. However, long-term use of dabrafenib may lead to the development of drug resistance, a phenomenon in which the drug gradually loses its effectiveness over the course of treatment. During dabrafenib treatment, some tumor cells may develop new BRAF mutations that can cause dabrafenib to lose its inhibitory effect on them.

Combine dabrafenib with other drugs, such as the MEK inhibitor trametinib, to increase the effectiveness of treatment and reduce the development of resistance. In clinical trials, it was seen that in patients with prior dabrafenib resistance, subsequent treatment with dabrafenib/trametinib showed limited clinical efficacy, with an overall response rate (ORR) of approximately 10% and modest increases in overall survival (OS) and progression-free survival (PFS), which may depend on the duration of prior BRAF inhibitor exposure.

The original drug of dabrafenib is relatively expensive and has been covered by medical insurance since it was launched in China. Currently only eligible patients are reimbursed. The price of each box of 50mg*120 capsules may be around around 10,000. The Turkish version of the original drug Dabrafenib sold overseas, Specifications 75mg*120 capsules, may cost around 10,000 per box (the price may fluctuate due to exchange rates). There are also relatively cheap generics of dabrafenib sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, Specifications produced by Laos Pharmaceutical Factory The price of 75mg*120 tablets per box may be more than 4,000 yuan (the price may fluctuate due to exchange rates).